Mortality outcomes and predictors of failed thrombolysis following STEMI thrombolysis in a non-PCI capable tertiary hospital: a 5-year analysis

[1]  D. Bartolini,et al.  Reasons for reperfusion delay in ST-elevation myocardial infarction and their impact on mortality , 2021, Journal of cardiovascular medicine.

[2]  E. Fabris,et al.  Early prognostic stratification and identification of irreversibly shocked patients despite primary percutaneous coronary intervention , 2021, Journal of cardiovascular medicine.

[3]  E. Mirrakhimov,et al.  Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: the ACVC-EAPCI EORP STEMI Registry of the European Society of Cardiology. , 2021, European heart journal.

[4]  Mahathar Abd Wahab,et al.  Impact of a binary triage system and structural reorganization of emergency department on health care workers exposed to suspected COVID-19 patients—a single-centre analysis , 2021, International Journal of Emergency Medicine.

[5]  E. Pivetta,et al.  After the first wave and beyond lockdown: long-lasting changes in emergency department visit number, characteristics, diagnoses, and hospital admissions , 2021, Internal and Emergency Medicine.

[6]  R. Gopar-Nieto,et al.  Pharmacoinvasive Strategy vs Primary Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction: Results From a Study in Mexico City , 2020, CJC open.

[7]  Enrico Fabrisa,et al.  COVID-19 impact on ST-elevation myocardial infarction incidence rate in a Italian STEMI network: a U-shaped curve phenomenon , 2021 .

[8]  T. Stewart,et al.  Clinical Factors Associated With Failed Thrombolysis in ST-Segment Myocardial Infarction (STEMI) in a Regional Setting , 2021, Heart, Lung and Circulation.

[9]  S. Iliceto,et al.  Characteristics and hospital course of patients admitted for acute cardiovascular diseases during the coronavirus disease-19 outbreak , 2020, Journal of cardiovascular medicine.

[10]  F. Guerra,et al.  Reduction in acute coronary syndromes during coronavirus disease 2019 global pandemic: data from the Marche region of Italy. , 2020, Journal of cardiovascular medicine.

[11]  Venkateshwarlu Eggadi,et al.  Safety and efficacy of streptokinase, tenecteplase, and reteplase in patients diagnosed with ST-elevation myocardial infarction: A comparative study , 2020, JOURNAL OF INDIAN COLLEGE OF CARDIOLOGY.

[12]  C. Reid,et al.  Comparative Overview of ST-Elevation Myocardial Infarction (STEMI) Epidemiology, Demographics, Management and Outcomes in 5 Asia-Pacific Countries - A Meta-Analysis. , 2020, European heart journal. Quality of care & clinical outcomes.

[13]  Jeroen J. Bax,et al.  Resource and Infrastructure-Appropriate Management of ST-Segment Elevation Myocardial Infarction in Low- and Middle-Income Countries , 2020, Circulation.

[14]  I. Patel,et al.  Characteristics of ST-elevation myocardial infarction with failed thrombolysis , 2020, Asian cardiovascular & thoracic annals.

[15]  Coronavirus Will Be in the Top 10 Causes of Death , 2020 .

[16]  R. Mandal,et al.  Assessment of ST Segment Resolution as a Predictor of Outcome in Acute Myocardial Infarction after Thrombolysis , 2019, International Journal of Contemporary Medical Research [IJCMR].

[17]  H. Hoque,et al.  Clinical Impacts of ST- Segment Non-Resolution after Thrombolysis for Myocardial Infarction , 2019, University Heart Journal.

[18]  G. Chakka,et al.  Comparison of Safety and Efficacy of Streptokinase and Tenecteplase in Patients of Myocardial Infarction , 2019 .

[19]  C. Upasani,et al.  A Randomized, Parallel Study to Compare Efficacy & Safety of Streptokinase vs Tenecteplase when Given in Correct Timelines in Patients of ST-Elevation Myocardial Infarction (STEMI) , 2018 .

[20]  Dr. Rajiv Girdhar.  Successful or Unsuccessful Thrombolysis with Streptokinase in Acute Myocardial Infarction: A Descriptive Study , 2018 .

[21]  Marco Valgimigli,et al.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). , 2018, European heart journal.

[22]  A. Phrommintikul,et al.  Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis , 2017, The Lancet.

[23]  H. Hariawan,et al.  Prediction of Failed Fibrinolytic Using Scoring System in ST Elevation Myocardial Infarction Patients , 2017 .

[24]  N. R. Rathod,et al.  A Comparative Study of Streptokinase V/S Tenecteplase in Hyper Acute Stage of Myocardial Infarction , 2016 .

[25]  V. Kundal,et al.  Failure of Thrombolysis with Streptokinase In Acute Myocardial Infarction Using ECG Criteria: An Observational Study , 2015 .

[26]  F. Werf.  The history of coronary reperfusion. , 2014 .

[27]  Jane A. Linderbaum,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[28]  G. Dente,et al.  Lytic failure in the current pharmacointensive ST-elevated acute myocardial infarction care: insights from a pilot real-world study , 2013, Journal of cardiovascular medicine.

[29]  Deepak L. Bhatt,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Circulation.

[30]  D. Atar,et al.  ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation , 2013 .

[31]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[32]  Y. Lee,et al.  Thrombolytic failure with streptokinase in acute myocardial infarction using electrocardiogram criteria. , 2008, Singapore medical journal.

[33]  Salim Yusuf,et al.  The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial. , 2008, European heart journal.

[34]  G. Clesham,et al.  Clinical implications of ST-segment non-resolution after thrombolysis for myocardial infarction. , 2004, Journal of the Royal Society of Medicine.

[35]  S. Yusuf,et al.  Relationship of Metabolic Syndrome and Fibrinolytic Dysfunction to Cardiovascular Disease , 2003, Circulation.

[36]  D. Combs,et al.  Pharmacokinetics and Pharmacodynamics of Tenecteplase in Fibrinolytic Therapy of Acute Myocardial Infarction , 2002, Clinical pharmacokinetics.

[37]  Assent investigators.  Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction , 2001, The Lancet.

[38]  M. D. Belder.  Acute myocardial infarction: failed thrombolysis , 2001 .

[39]  E. Antman,et al.  TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation: An Intravenous nPA for Treatment of Infarcting Myocardium Early II Trial Substudy , 2000, Circulation.

[40]  F. Werf.  Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial , 1999, The Lancet.

[41]  E. Braunwald,et al.  Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators. , 1999, American heart journal.

[42]  G Barbash,et al.  Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial , 1999, The Lancet.

[43]  A. Sinkovic,et al.  Pretreatment plasminogen activator inhibitor-1 (PAI-1) levels and the outcome of thrombolysis with streptokinase in patients with acute myocardial infarction. , 1998, American heart journal.

[44]  E. Topol.  A comparison of reteplase with alteplase for acute myocardial infarction. , 1998, The New England journal of medicine.

[45]  T. Investigators,et al.  A comparison of reteplase with alteplase for acute myocardial infarction , 1997 .

[46]  R. Califf,et al.  Metaanalysis of five reported studies on the relation of early coronary patency grades with mortality and outcomes after acute myocardial infarction. , 1996, The American journal of cardiology.

[47]  Paolo Berger,et al.  Randomized, double blind comparison of reteplase double bolus administration with streptokinase in acute myocardial infarction (inject): Trial to investigate equivalence , 1996 .

[48]  R. Wilcox,et al.  Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence International Joint Efficacy Comparison of Thrombolytics , 1995, The Lancet.

[49]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION , 1986, The Lancet.